1. Home
  2. MCRB vs FATN Comparison

MCRB vs FATN Comparison

Compare MCRB & FATN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MCRB
  • FATN
  • Stock Information
  • Founded
  • MCRB 2010
  • FATN 1989
  • Country
  • MCRB United States
  • FATN United States
  • Employees
  • MCRB N/A
  • FATN N/A
  • Industry
  • MCRB Biotechnology: Pharmaceutical Preparations
  • FATN
  • Sector
  • MCRB Health Care
  • FATN
  • Exchange
  • MCRB Nasdaq
  • FATN NYSE
  • Market Cap
  • MCRB 125.7M
  • FATN 113.0M
  • IPO Year
  • MCRB 2015
  • FATN 2025
  • Fundamental
  • Price
  • MCRB $13.99
  • FATN $5.87
  • Analyst Decision
  • MCRB Hold
  • FATN
  • Analyst Count
  • MCRB 4
  • FATN 0
  • Target Price
  • MCRB $73.67
  • FATN N/A
  • AVG Volume (30 Days)
  • MCRB 148.0K
  • FATN 33.0K
  • Earning Date
  • MCRB 08-06-2025
  • FATN 07-30-2025
  • Dividend Yield
  • MCRB N/A
  • FATN N/A
  • EPS Growth
  • MCRB N/A
  • FATN N/A
  • EPS
  • MCRB 8.98
  • FATN 0.16
  • Revenue
  • MCRB N/A
  • FATN $16,474,485.00
  • Revenue This Year
  • MCRB N/A
  • FATN N/A
  • Revenue Next Year
  • MCRB N/A
  • FATN N/A
  • P/E Ratio
  • MCRB $1.53
  • FATN $41.52
  • Revenue Growth
  • MCRB N/A
  • FATN N/A
  • 52 Week Low
  • MCRB $6.53
  • FATN $5.60
  • 52 Week High
  • MCRB $27.40
  • FATN $23.27
  • Technical
  • Relative Strength Index (RSI)
  • MCRB 58.12
  • FATN N/A
  • Support Level
  • MCRB $12.15
  • FATN N/A
  • Resistance Level
  • MCRB $15.40
  • FATN N/A
  • Average True Range (ATR)
  • MCRB 1.36
  • FATN 0.00
  • MACD
  • MCRB -0.12
  • FATN 0.00
  • Stochastic Oscillator
  • MCRB 65.29
  • FATN 0.00

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About FATN FATPIPE INC

Fatpipe Inc is a pioneer in enterprise-class, application-aware, secure SD-WAN solutions for organizations, including enterprises, communication service providers, security service providers, government organizations, and other middle-market companies. It is engaged in delivering principal enterprise-class networking software technology. The company is dedicated to continually improving the way organizations connect, ensuring their networks are secure, reliable, and supporting their continued success. Its commitment lies in empowering its customers with a seamless and dependable connectivity infrastructure that safeguards their critical data and fosters business continuity. Further, the company's goal is to ensure its customers have unparalleled insights into their network operations.

Share on Social Networks: